Search

everythinglearnresearchcommunity

for

Search:↓

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.

Ritlecitinib has common side effects like headache and acne, and unexpected ones like diabetes and thyroid issues.

Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Switching to ritlecitinib improves hair regrowth and well-being in severe alopecia areata patients.

Tridax procumbens may help treat diabetes.

Topical aprepitant reduces skin rash and hair loss caused by cancer treatment.

Adding aripiprazole to the treatment improved hair-pulling symptoms in a teenager.

Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Tofacitinib treatment is used for teenagers with alopecia areata.

Oral tofacitinib can significantly improve recalcitrant lichen planopilaris.

Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.

Letrozole may help prevent seizures by reducing certain hormone levels.

A new compound shows promise as a topical treatment for hair loss.

PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.

Upadacitinib may effectively treat twenty-nail dystrophy without causing pain.

Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.

The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.

TAT-GILZ peptide promotes hair growth by boosting stem cell activity.

PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

Ritlecitinib shows promise in improving hair regrowth in adolescents with alopecia areata.

Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.

The FDA approved a new Pfizer drug for hair loss in teens.

Liraglutide with metformin reduces body fat and improves blood sugar control better than metformin and inositol in women with prediabetes.

Tofacitinib is effective and safe for elderly patients with ulcerative colitis.